Skip to main content

Table 4 Probabilities associated with infection necessary in a “One-Health” cost model

From: A one health framework to estimate the cost of antimicrobial resistance

Data element Probability
Mortality (overall)
(Human and animal health)
Probability of dying WITH a MDR infection, for a patient/animal infected (by the subgroups defined in “epidemiology”)
Treatment efficacy of 2nd line, 3rd line etc. drugs
Mortality (attributable)
(Human and animal health)
Probability of dying FROM an MDR infection, for a patient/animal infected (by the subgroups defined in “epidemiology”)
Treatment efficacy of 2nd line, 3rd line etc. drugs
Morbidity (Human and animal health) Probability of developing long term consequences (e.g chronic or recurrent infections, long term disability from ICU stay, lower QoL, etc) from AMR infections, out of all patients infected
Probability of developing adverse events, if treated with 2nd, 3rd etc. line drugs
Longer hospital stay in patients/animals with AMR infections, compared to those with the same, but not AMR, infection
Longer ICU stay for patients/animals with AMR infections
Additional diagnostic procedures for drug resistant infections (Human and animal health) Probability of undergoing additional diagnostic procedures (e.g. imaging to diagnose site of infection or foci of distant infectious metastatic foci, FollowupFollow-up blood cultures, etc)
Screening (Humans / animals) Probability of starting a screening programme when there is an infected patient/animal (Number of colonised patients to trigger a screening programme) (humans / animals)
Insurance Probability of having an insurance to cover extra AMR costs (Please note that pet insurance is rare in most countries)